Accelerated Approval Conversion Could Mean ‘Breakthrough’ Loss

Product sponsors holding “breakthrough therapy” status may risk losing the designation if and when a competitor with accelerated approval successfully completes confirmatory trials.

However, discussion at a Brookings Institution meeting April 24 suggests that conversion from accelerated to regular approval is not an automatic death knell for the breakthrough designation held by another...